In 2025, the team will enhance the cytotoxicity of DOT cells by using butyrate to upregulate NKG2D expression to improve the targeting of tumor cells, and block both PD-1 and TIGIT to treat colorectal cancer [125]. The gene discussed is KLRK1; the disease is neoplasm.